City Therapeutics Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good. Hi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I'd like to welcome Andy Orth, the CEO of City Therapeutics. City just recently did their IPO, and it's great to have Andy here. He's going to go through a presentation and tell you about the company, and then we'll do some Q&A at the end as well. Thanks for joining us, Andy.
Great. Good. Thanks, Morrie. Good afternoon, everybody. I'm Andy Orth. I'm the CEO of City Therapeutics. City was founded roughly three years ago with the bold vision in mind of leading the next generation of RNAi therapeutics. The underlying belief set here is that RNAi is going to be a very large, very important modality, and there's room for both innovation as well as continued use of the existing technologies. Within the company, we did two things very, very quickly. One, we stood up three programs, which are all clinical stage at this point, with existing siRNA technology using GalNAc delivery to the liver. I'll walk you through each of these programs here in a moment. At the same time, we brought in a novel technology for what we think is going to be the future, which is extrahepatic delivery.
This novel technology is called cityRNA, cleavage-inducing tiny RNA, and it's actually a smaller trigger mechanism than an siRNA. We're innovating again on the extrahepatic side. I'll share a little bit of that with you as we go, but I think we're going to spend the majority of the time here focusing on the three clinical stage programs today. I do want to highlight that City was founded by some of the original pioneers in RNAi, John Maraganore, Phil Zamore, some of the other scientific names that if you followed the space, you're very familiar with. We also have a deep employee base who've worked on seven of the eight approved RNAi medicines to date. The distinguishing factor about City going forward is going to be its platform, and within that platform, we focus disproportionately on what I call that trigger molecule.
Within the siRNA space, or the approved canonical technologies that are out there today, not all siRNAs are built the same. There's a number of siRNA companies popping up all over the world, and as we go forward, we're going to begin to see differences in how these molecules are constructed. Making a potent siRNA is difficult, but not out of the reach of many. Making a potent and specific, and specific means clean, with few, if any, off-target effects is in fact challenging. This is something we, knowing we employ some of the people that discovered the original siRNAs and GalNAc delivery to the liver, do very, very well, and we think this is going to distinguish us in these lead siRNA programs. Then the future for us are these cityRNAs.
Again, a smaller trigger molecule that we think is going to be beneficial when we get to extrahepatic delivery. Importantly, this was a technology that was invented at Ohio State. Kotaro Nakanishi is one of our co-founders. He discovered this technology there. We have in-licensed that technology in total, and we have built a significant IP moat around that. Our pipeline that I'm going to show you shortly today uses siRNAs. Any programs that we start in the future will use these novel proprietary cityRNAs. This is the pipeline as it stands today. Five programs, three liver-delivered siRNAs. We have Factor XI for thromboembolic disease, RBP4 for Stargardt with a potential follow-on in GA, and then finally TFR2 for anemia of chronic disease. I'm going to walk you through each of these in detail here in a moment.
I do want to highlight the two significant partnerships we've done to date. One is Bausch + Lomb. This was a partnership for intravitreal administration of RNAi. They gave us a target that they want to knock down against geographic atrophy. We've taken this from the beginning of a partnership to the point where we have excellent data in both the rabbit tolerability model as well as NHP. This is an important program in that we're in the lead and alone in a space of intravitreal administration of RNAi. Previous programs have attempted to get to this space, and all have fallen to the wayside due to tolerability aspects. These were generally using lipids to deliver the cargo, the siRNA. We're using a peptide. This was discovered in-house. It's a novel technology. Once we hand Bausch + Lomb their delivery candidate, which we're expected to do very near future, the delivery technology remains with us.
This opens up a host of other ocular targets for safe, effective RNAi administration in our future, and we'll be sharing those programs with you next year. The second program we have that's partnered is with Biogen. Biogen is a little different in this case. They brought a trans-BBB delivery technology to us. They came to us knowing our ability to engineer siRNAs. We have built that with them, conjugated it, working back and forth at this point, and we expect to hand them a development candidate in the middle of next year. Importantly, at the top of this slide, I do want to highlight this fact.
The goal of the company, and we're on track, is to submit one to two INDs or IND equivalents annually ad infinitum. Outside of the five programs you're looking at here on the screen, we have a number of earlier stage programs across liver, ocular, and CNS. You will see those disproportionately become extrahepatic in our future, and we're well on track for this one to two INDs per year. With that, let's dive into the three liver programs. The first is Factor XI for thromboembolic diseases. Factor XI is a genetically validated target that safely prevents thrombi. There is a number of genetic proof people walking around in the world right now who are completely safe, they have no bleeding issues, but they have vastly fewer strokes, DVTs, PEs, et cetera. This is a competitive space.
There are small molecules, antibodies, and RNAi programs all going after this same target. City's position for our molecule is to go where the standard of care, oral anticoagulants, Xarelto, ELIQUIS, cannot play today. Specifically, DOAC-ineligible AFib, secondary stroke prevention, secondary VTE prophylaxis, et cetera. We are currently in the middle of our phase I program for Factor XI. We have completed dosing for all part A at the 15, 50, and 150 mg, and have just begun dosing in part B, which is 300 and 600. Importantly, with the phase I, we have organized it so that part B and part C are almost close to real patient populations. Part B is Factor V Leiden patients. These are individuals who are predisposed to clot. Part C are individuals who have had a prior VTE.
Another point I want to note, back to what I mentioned in the beginning of the presentation, that not all siRNA molecules are made equally. I am going to show you in a moment just how potent our Factor XI molecule is. We are going to start with how clean or how specific this molecule is. RNAi has progressed over the years, and at this point in time, we are able to engineer these molecules with minimal, and in this case, no undesired off-target impacts. Not all RNAi companies are doing this well. You are going to see at some point in the near future here clinical stage programs that end up having to go backwards in order to retool this molecule. I and some other people in the room here had this experience at Alnylam. It comes from engineering know-how and wisdom.
The human is the most sensitive species to unwanted liver impacts from RNAi, and you often do not discover it until it gets into the clinic when it needs to go back and again, get retooled. This is the early data from our Factor XI molecule. I am thrilled to say we have beautiful dose-dependent knockdown when you are delivering siRNA to the liver. These early curves are exactly what you want to see. We reached 61% at 15 mg, 79% at 50 mg, and 85% knockdown at 150 mg. We are going to share the full totality of this data, these three doses, as well as early data from the 300 mg dose at ASH in New Orleans in a few weeks. Importantly here, a best-in-class profile in this space looks like 95% plus knockdown with every six-month dosing with a single shot. We are well on our way to achieving this profile.
Here is a quick snapshot of the trial design we just went through, part A, part B, and part C on phase I. Part B, when completed, allows us to go directly into the phase II study, which is a total knee replacement study. This is a well-trodden path in the thromboembolic field. We will start this phase II study in the middle of next year, and then move beyond that phase II study in TKA to a host of those other indications that I mentioned on the first slide. Moving on from Factor XI to our second program, which is RBP4 for the treatment of Stargardt disease. Stargardt is a rare disease, approximately 30,000 patients in the U.S., conservatively. Most inherited retinal disease, there are zero approved therapies for this today.
It often strikes in adolescence, and these patients reach legal blindness at some point in their 20s or beyond. Again, completely unserved, unmet need here today. Additionally, with this molecule, there are some common hallmarks between the mechanism we're about to talk about in a moment with Stargardt and geographic atrophy, and we were looking to start a trial in geographic atrophy at the end of 2027. RBP4 is interesting in a number of fronts, but namely, we're using a liver-directed siRNA to treat an ocular disease. What we're essentially doing is inhibiting RBP4, which has one job and one job only, and that's to deliver vitamin A to the eye.
By inhibiting this and inhibiting vitamin A that's reaching the eye, you're preventing the metabolite or the feeder basically for a toxic metabolite, which the mutation here in the ABCA4 gene causes, which causes the deposits that lose vision in Stargardt and partly into GA as well. What we're looking at here is our NHP data. Importantly, this again is showing us with the ability to do dose-dependent knockdown. On the left, you're seeing RBP4. On the middle panel here, you're seeing what that does to vitamin A or retinol in the systemic blood, and then the correlation of these two. What we've shown is that by knocking down RBP4, we can limit vitamin A delivery to the eye, et cetera. Importantly, this is a clinically validated target. There's a small molecule, Belite Bio has tinlarebant that's a bit in front of us.
They are using the same target with small molecule inhibition, all the peak troughs that come with it. We are coming behind them what we think is a superior approach here for the disease. The phase I study is ongoing. I'm happy to say we dosed our first healthy participant two weeks ago, and we'll continue here in part A. Importantly, with part B and part C, we're going to enter Stargardt patients. Again, on top of this, these patients will be screened to be very similar to those we're going to enter into the pivotal trial. The purpose of that is that we'll roll these patients over from part B and part C into a long-term open-label extension. We're measuring various efficacy metrics, what we'll see in the phase III, et cetera, safety, and so forth.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
